First Time Loading...

BioXcel Therapeutics Inc
NASDAQ:BTAI

Watchlist Manager
BioXcel Therapeutics Inc Logo
BioXcel Therapeutics Inc
NASDAQ:BTAI
Watchlist
Price: 1.87 USD 0.54% Market Closed
Updated: May 28, 2024

BioXcel Therapeutics Inc
Total Current Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

BioXcel Therapeutics Inc
Total Current Liabilities Peer Comparison

Comparables:
ABBV
GILD
AMGN
VRTX
REGN

Competitive Total Current Liabilities Analysis
Latest Figures & CAGR of Competitors

Company Total Current Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
BioXcel Therapeutics Inc
NASDAQ:BTAI
Total Current Liabilities
$31.5m
CAGR 3-Years
37%
CAGR 5-Years
36%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Total Current Liabilities
$41.5B
CAGR 3-Years
9%
CAGR 5-Years
24%
CAGR 10-Years
21%
Gilead Sciences Inc
NASDAQ:GILD
Total Current Liabilities
$13B
CAGR 3-Years
10%
CAGR 5-Years
7%
CAGR 10-Years
8%
Amgen Inc
NASDAQ:AMGN
Total Current Liabilities
$19.7B
CAGR 3-Years
15%
CAGR 5-Years
9%
CAGR 10-Years
9%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Total Current Liabilities
$3.8B
CAGR 3-Years
25%
CAGR 5-Years
28%
CAGR 10-Years
26%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Total Current Liabilities
$3.6B
CAGR 3-Years
4%
CAGR 5-Years
19%
CAGR 10-Years
28%

See Also

What is BioXcel Therapeutics Inc's Total Current Liabilities?
Total Current Liabilities
31.5m USD

Based on the financial report for Mar 31, 2024, BioXcel Therapeutics Inc's Total Current Liabilities amounts to 31.5m USD.

What is BioXcel Therapeutics Inc's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 5Y
36%

Over the last year, the Total Current Liabilities growth was 9%. The average annual Total Current Liabilities growth rates for BioXcel Therapeutics Inc have been 37% over the past three years , 36% over the past five years .